You are on page 1of 9

Clinics in Dermatology (2011) 29, 1523

Pruritus in the elderly


Adam Reich, MD a , Sonja Stnder, MD, PhD b , Jacek C. Szepietowski, MD, PhD a,
a

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Chalubinskiego 1,


50-368 Wroclaw, Poland
b
Neurodermatology and Competence Center Pruritus, Department of Dermatology, University Hospital Mnster,
Von-Esmarch-Strasse 58, D-48149 Mnster, Germany

Abstract Pruritus is an unpleasant sensation leading to the desire to scratch. It is the most common
symptom in dermatology, and various skin and systemic diseases can be associated with the presence of
itching. Pruritus may also be provoked by numerous drugs. Although the exact epidemiologic data are
still absent, it is generally accepted that elderly people frequently suffer from pruritus, and the problem
of itching in this population remains a challenge for clinicians. The elderly often complain of numerous
comorbidities that complicate the determination of the cause of pruritus, as well as its treatment.
Physical and mental deprivation may complicate proper assessment of pruritus severity and negatively
impair compliance with complex antipruritic therapies. Taking also into account heterogeneity of
possible causes of pruritus, every patient with pruritus must be handled individually, regarding the
diagnostic procedures and antipruritic therapy.
2011 Elsevier Inc. All rights reserved.

Introduction
Pruritus is defined as an unpleasant sensation that may
lead to intensive scratching.1 It is the most common
symptom in dermatology, one that can occur with or without
concomitant visible skin changes. Pruritus may be considered as acute (lasting less than 6 weeks) or chronic (lasting
more than 6 weeks).1 It can be localized or generalized.
Various skin and systemic diseases have been characterized
as being associated with the presence of itching (Tables 1
and 2), and different mechanisms have been proposed to
explain its origin. We have summarized current knowledge
about the problem of itching in the elderly population, hoping
that we will encourage physicians and researchers to concen Corresponding author. Tel.: +48 71 327 0941.
E-mail address: jszepiet@derm.am.wroc.pl (J.C. Szepietowski).
0738-081X/$ see front matter 2011 Elsevier Inc. All rights reserved.
doi:10.1016/j.clindermatol.2010.07.002

trate on this important topic in the near future, because any


new data on this issue are very warmly welcomed.

Pruritus classification
A new, two-step classification of pruritus has recently
been proposed by the International Forum for the Study of
Itch (IFSI).1 The IFSI classification was based on two
previous classifications of itching2,3 but additionally included important aspects of our current understanding of pruritus.
The IFSI classification1 distinguishes three groups of pruritic
individuals: those having pruritus on diseased skin (group I),
pruritus on nondiseased skin (group II), and pruritus with
secondary skin scratch lesions (group III). It also specifies six
categories of underlying pruritogenic diseases: dermatologic,
systemic, neurologic, psychogenic, mixed, and other

16
Table 1

A. Reich et al.
Pruritic skin diseases occurring in the elderly

1. Xerosis (skin dryness)


2. Inflammatory diseases
Dermatitis (all forms)
Dyshydrotic dermatitis
Drug reactions
Urticaria
Atopic dermatitis/neurodermatitis (rare)
3. Erythematous papulosquamous diseases
Seborrheic dermatitis
Psoriasis
Palmoplantar pustulosis
Lichen planus
Pityriasis rubra pilaris
Darier disease
Hailey-Hailey disease
Grover's disease
Polymorphic light eruptions
4. Autoimmune blistering diseases
Bullous pemphigoid
Acquired epidermolysis bullosa
Dermatitis herpetiformis
Pemphigus vulgaris (rarely)
5. Autoimmune connective tissue diseases
Dermatomyositis
Systemic sclerosis
Sjgren syndrome
6. Skin infections and infestations
Herpes simplex
Herpes zoster
Tineas
Candidal intertrigo
Malassezia folliculitis
Ofuji's disease
Scabies
Lice (pediculosis)
Cutaneous larva migrans
Insect bites and arthropod reactions
7. Rosacea
8. Mastocytosis
9. Cutaneous lymphomas
Mycosis fungoides and its variants
Szary syndrome

pruritus.1 In general, patients from group I belong to the


category of dermatologic pruritus. The most important skin
diseases occurring in elderly population that can be pruritic
are listed in Table 1.
Primary skin changes may sometimes be confounded by
secondary scratch lesions. They include excoriations, crusts,
lichenification, papules, and nodules, and are produced by
chronic scratching, rubbing, or pinching of the skin. These
lesions may resolve with hypopigmentations and hyperpigmentations or atrophic scars. Thus, patients with dermatologic pruritus can occasionally be accounted in group III;
however, secondary scratch-related lesions may also frequently appear in group II patients (pruritus on nondiseased

skin) if the itching lasts sufficiently long (usually several


months to years) and is of significant severity.
Group II and III patients may suffer from systemic,
neurologic, or psychogenic pruritus. Systemic pruritus is
defined as pruritus arising from disease of organs other than
the skin, such as liver, kidney, or blood. This type of
pruritus should also be differentiated from neurologic
pruritus, which can arise from neuronal damage (neuropathic itch) or can have neurogenic origin without neuronal
damage, such as itching after administration of opioids
(neurogenic itch). Systemic diseases including also some
neurologic disorders that may be responsible for pruritus are
mentioned in Table 2.
Psychogenic pruritus, called also somatoform pruritus,
constitutes a distinct category and may accompany various
psychiatric conditions. The diagnostic criteria of somatoform
pruritus without underlying psychiatric disorder have been
recently proposed.4,5 (Table 3).
More than one disease may be responsible for pruritus in
some patients, and this type of pruritus should be categorized
as mixed. Finally, no underlying disease can be identified
in a number of patients, and these individuals should be

Table 2
pruritus

Systemic diseases accompanied by generalized

Liver diseases
Primary biliary cirrhosis
Primary sclerosing cholangitis
Extrahepatic cholestasis
Hepatitis B and C
Kidney diseases
Chronic kidney insufficiency
Hematologic diseases
Polycythemia vera
Hodgkin disease
Non-Hodgkin lymphomas
Leukemias
Myeloma multiplex
Iron deficiency
Systemic mastocytosis
Hypereosinophilic syndrome
Myelodysplastic syndromes
Endocrine disorders
Hyperthyroidism
Hypothyroidism
Hyperparathyroidism
Diabetes
Neurologic diseases (neuropathic pruritus)
Brain injury/tumor (frequently unilateral pruritus)
Sclerosis multiplex
Small fiber neuropathy
Solid tumors (paraneoplastic pruritus)
Carcinoid syndrome
Infectious diseases
HIV infection/AIDS
Infestations

Pruritus in the elderly


Table 3

Diagnostic criteria for psychogenic pruritus a

Criteria

Definitions

Compulsory (all must Localized or generalized pruritus


be fulfilled)
without primary skin lesions
Pruritus lasting for more than 6 weeks
No somatic cause of pruritus
Optional (at least 3
A chronologic relationship of pruritus
must be present)
with one or several life events that could
have psychologic repercussions
Variations in intensity associated with
stress
Nocturnal variations
Predominance during rest or inaction
Associated psychologic disorder
Pruritus that could be improved by
psychotropic drugs
Pruritus that could be improved by
psychotherapy
a

Data on ref [4].

accounted in the other category. They can sometimes be


reclassified later on to a different category if a reason for the
pruritus is established.1

Drug-induced pruritus
Owing to a high frequency of chronic diseases present in
the elderly population, older people often simultaneously
take a number of medicines. Many systemic and topical
drugs can induce pruritus.6 Although drug-induced pruritus
(pruritus without skin rash) is not a distinct category but
summarized under systemic origin according to the IFSI
classification, this adverse effect should be taken into
account when assessing patients with chronic itch. Frequently, the cause of itching is not a systemic or neurologic
disease, but rather the treatment that was initiated.
The most important drugs that might be responsible for
chronic pruritus have been listed in Table 4. The pathogenesis of drug-induced pruritus differs depending upon the
causative agent. Acute pruritus may be secondary to druginduced skin lesions; however, a number of other possible
mechanisms of drug-induced chronic pruritus have been
postulated, including cholestatic liver injury, xerosis of the
skin, deposits of a drug or its metabolites in the skin,
phototoxicity, or neurologic mechanisms. Frequently, the
underlying mechanism is unknown.6
Drug-induced pruritus may be localized or generalized
and can start with the first dose or may be delayed in time
for several weeks or even months.7-9 It may resolve
shortly after the drug is discontinued10 or may persist
even for several months or years after treatment withdrawal.11-13 A clear time-relation has been described for
some drugs, and interruption of the drug leads to cessation
of pruritus. Usually, pruritus lasts in this group less than 6

17
weeks, fulfilling the definition of acute pruritus. With other
drugs, pruritus lasts much longer due to the underlying
mechanisms; for example, in hydroxyl ethyl starch-induced
Table 4

List of drugs that could induce pruritus a

Drug group
Antihypertensive drugs

Examples

Angiotensin-converting
enzyme inhibitors
Angiotensin II antagonists
(sartans)
-Adrenergic blockers
Calcium channel blockers
Methyldopa
Sildenafil
Antiarrhythmic drugs
Amiodarone
Anticoagulants
Ticlopidine
Fractionated heparins
Antidiabetic drugs
Biguanides
Sulfonylurea derivants
Hypolipemic drugs
Statins
Antibiotics and
Penicillins
chemotherapeutics
Cephalosporins
Macrolides
Carbapenems
Monobactams
Quinolones
Tetracyclines
Lincosamides
Streptogramin
Metronidazole
Rifampin
Thiamphenicol
Trimethoprim/
sulfamethoxazole
Antimalarials
Psychotropic drugs
Tricyclic antidepressants
Selective serotonin reuptake
inhibitors
Neuroleptics
Antiepileptics
Carbamazepine, fosphenytoin,
oxcarbazepine, phenytoin,
topiramate
Cytostatics
Chlorambucil
Paclitaxel
Tamoxifen
Cytokines, growth factors,
Granulocyte-macrophage
and monoclonal antibodies colony-stimulating factor
Interleukin 2
Matuzumab
Lapatinib
Plasma volume expanders
Hydroxyethyl starch
Others
Antithyroid agents
Nonsteroidal antiinflammatory
drugs
Corticosteroids
Sex hormones
Opioids
Xanthine oxidase inhibitors
a

Table based on ref [6].

18
pruritus, the symptom is induced by neuronal storage, which
is relieved after degradation of the substance. This can
be grouped as chronic pruritus because it lasts for more than
6 weeks.6
In addition, many drugs were described to induce chronic
pruritus by unknown mechanisms, presenting another group
of chronic drug-induced pruritus. Therapy is very difficult in
this group, including the decision to interrupt or change the
drug. According to our experience, interruption for at least
6 weeks is necessary to prove that chronic pruritus is due
to the accused drug.

Epidemiology of pruritus in elderly


Pruritus is a frequent phenomenon in elderly people,
defined as individuals aged older than 65 years. Remarkably,
the term senile pruritus or Willan's itch was even
introduced to describe chronic pruritus of unknown origin in
old-age individuals14,15; however, despite its high frequency,
the problem of pruritus in the elderly has not been studied
well so far. It is still not exactly known whether senile
pruritus can be handled as a separate entity or is a term
referring to chronic pruritus that was inappropriately
diagnosed; nevertheless, the burden of chronic itch among
elderly people represents a growing challenge due to the
changing demographic distribution.16
The prevalence of chronic itching in older people has not
been well defined. Only a few studies on rather small
populations or with significant selection bias are available.16
A study assessing retrospectively more than 4000 patients aged
65 years, found that pruritus was responsible for 11.5% of
admissions, being the third most common cause of hospitalization.17 In the oldest group (aged N85 years), the frequency
of chronic pruritus as the major dermatologic illness was even
higher, accounting for 19.5% of analyzed individuals;
however, many other patients in that study suffered from
skin conditions frequently connected with itching, such as
eczematous dermatitis, so the true itch frequency in studied
population is hard to establish.17 The high rate of admittance
due to pruritus indicates the importance of this symptom in
older people. In another study18 among 1556 nursing home
patients, pruritus or related diseases were found in about twothirds. In a study of 68 patients aged between 50 and 91 years,
pruritus was the most common complaint for the skin,
accounting for 29% of all complaints and two of three
cutaneous complaints subjectively graded as severe.19

Pathophysiology of aged skin


Skin aging is a result of a combination of chronologic and
environmental influences.20 It involves intrinsic, hormonal,
biologic, and genetic factors as well as extrinsic, noxious
stimuli such as life-long accumulation of ultraviolet (UV)

A. Reich et al.
radiation, pollution, or nicotine.21-23 Aging skin is characterized by atrophy of the epidermis and dermis due to loss of
collagen, degeneration of the elastic fibre network, and loss
of hydration. Characteristic of aging is a progressive loss of
function and structural integrity resulting in impaired
immune response and skin barrier function, vascular
impairment, metabolic imbalance of reactive oxygen species,
and components of the extracellular matrix.24,25 Hence,
molecular mechanisms that protect and defend against
extrinsic factors decrease progressively over a lifetime.
Besides the natural aging of the skin, a higher rate of
comorbidity, decreased mobility, and drug-induced adverse
effects are additional reasons that elderly people are at higher
risk for skin-related as well as pruritic disorders.20,25
Clinically, aged skin is characterized by atrophy, wrinkling,
fragility, alterations in pigmentation, a higher frequency of
benign and malignant tumors, and a greater tendency to
xerosis.26,27 Altogether, these factors contribute to a greater
susceptibility to dermatologic diseases and pruritus.
Pruritus in elderly patients is frequently associated with
dry skin.15,20,28 Advanced forms of xerosis usually present as
asteatotic dermatitis with fine scaling due to the loss of
naturally moisturizing free fatty acids in the stratum
corneum.20,29 Superficial cracks and polygonally fissures
are characteristic for this skin condition, first described as
eczema craquel.20

Evaluation of pruritus
A very complex and heterogenous pathogenesis of
pruritus makes a determination of the cause of itching a
significant challenge for any physician treating patients with
pruritus. For that reason, every patient with itching has to be
considered individually because this symptom may be a
sign of many, completely different diseases with various
prognosis. The proper antipruritic therapy can be successful,
however, if the underlying cause is identified. Although the
reason of pruritus cannot be determined in some people
despite a thorough examination, the proper diagnostic
procedures can identify the underlying cause in most
pruritic individuals.30
Every patient with pruritus should undergo careful history
and full physical and dermatologic examination. A detailed
history of itching episodes should begin with inquiries into
onset, location, diurnal rhythm, and alleviating or aggravating factors surrounding an itching period.20 Abrupt onset of
itch is uncommon for systemic causes of pruritus and is more
frequently observed in drug reactions, infestations, and
contact dermatitis.15 Worsening of pruritus after showering
is typical for asteatotic dermatitis but may also be seen in
aquagenic pruritus accompanying polycythemia vera. An
increase of pruritus during the night is observed in nearly all
types of itch, but is especially characteristic for scabies. The
patient history should also include a detailed data about

Pruritus in the elderly


Table 5 Basic laboratory investigations recommended in
pruritic patients without primary skin lesions
Blood smear with differential blood count
C-reactive protein level or erythrocyte sedimentation rate
Serum iron level (in patients with anemia)
Serum urea and creatinine level
Liver function tests (total bilirubin, free bilirubin, serum
aminotransferase activity, serum alkaline phosphatase
activity)
Serum glucose level
Thyroid gland function tests (TSH, fT3, fT4)
Stool examination for parasite detection

concomitant diseases, all medicines taken, symptoms of


pruritus in close relatives, history of travelling, presence of
skin lesions, and potential allergens at home or at places
where the patient is living.
The intensity of pruritus can be assessed by a visual
analog scale (VAS), which is the method most often used due
to its simplicity. The patient indicates the intensity of itching
on a 10-cm-long line, starting from 0 (no pruritus) to 10 (the
worst pruritus you can imagine).31,32 Although this is a well
established and easy method of pruritus assessment, some
older people, especially for those with cognitive problems,
may have difficulty estimating the itching with the VAS. In
these individuals, a 5-point scale (0 = no pruritus, 1 = weak
pruritus, 2 = moderate pruritus, 3 = severe pruritus, 4 = very
severe pruritus) might be more suitable.
During the physical examination, any signs of a rash
should be sought on the skin. It is also important to palpate
lymph nodes, the thyroid gland, and the abdomen. Close
inspection of the hair and nails may provide important clues
for systemic disease. If no primary skin symptoms can be
found, basic laboratory investigations as listed in Table 5
should be performed. Depending on achieved results, more
detailed diagnostic procedures may be recommended.20,30

Overview of pruritus treatment


The treatment of pruritus consists of general measures and
directed antipruritic therapies.33 During treatment, every
patient should be instructed about the necessity of wearing
sheer clothes, avoiding hot baths, alcohol, and spicy foods,
keeping proper humidity of rooms, and avoiding contact with
wool and animal fur. Irrespectively of the cause of itching,
skin dryness worsens each type of pruritus. Thus, all patients
should regularly moisturize their skina twice-daily
application of an emollient is recommended. A large number
of formulations are currently available; among them, those
containing 5% to 10% urea or enabling the regeneration of
epidermal lipids can be prescribed. The patient should be
able to test several preparations to choose the optimal one.
Oil baths with natural or mineral oils may also help to

19
decrease xerosis. Furthermore, localized pruritus may be
diminished with cold wet dressings. Keeping the nails short
in patients with severe pruritus may prevent excoriations and
other secondary scratch lesions.

Topical therapies
Cooling agents
Some substances, like menthol, may decrease the
intensity of itching due to evoking a cooling effect by
activation of low temperature receptors in the skin. The
major limitation of menthol usage is a short-term efficacy,
usually lasting for less than 30 minutes, and the potential
irritant property of this compound. Currently, a huge hope is
put on novel agents (eg, ilicin) that will produce a longlasting cooling effect on the skin.
Anaesthetics
Formulations based on benzocaine or lidocaine are the
most widely used among anesthetics. They may be useful in
localized pruritus, especially in neuropathic pruritus; however, they can induce allergic contact dermatitis and may
induce side effects in the circulatory system if applied too
frequently or used for a long time.33 Another compound with
weak anesthetic properties is 3% polidocanol. It has been
used in therapy for itching accompanying psoriasis, atopic
dermatitis, and other forms of dermatitis, and in uremic
pruritus.34,35
Antihistamines
Doxepin (5%) is effective in atopic and contact dermatitis
and in microbic dermatitis.36-38 The drug should be applied
to a maximum of 10% of body surface. The total daily dose
must not exceed 3 grams. The antipruritic effect is observed
about 15 minutes after application. Other topical antihistamines have limited efficacy and may induce contact allergy
and are therefore not preferable.
Capsaicin
Capsaicin owes its antipruritic properties by desensitization of sensory nerve fibers, thus interrupting the
conduction of cutaneous pruritus and burning pain. The
application of capsaicin is connected with burning sensations during the first days of usage. To prevent this
problem, a 0.025% capsaicin should be used initially, and
subsequently, the concentration can be slowly increased to
0.1%. Capsaicin has been shown effective in the treatment
of notalgia paraesthetica (localized pruritus in the scapular
region of the back), prurigo nodularis, and in uremic
pruritus.33,39,40
Corticosteroids
Topical corticosteroids have limited value in the treatment of pruritus. They might only be effective in inflammatory skin conditions by decreasing inflammation and,
secondarily, pruritus.2,33

20
Calcineurin inhibitors
Calcineurin inhibitors (pimecrolimus, tacrolimus) are
potent antipruritic drugs in patients with atopic dermatitis.
Although some initial reports also suggested their value in
other pruritic conditions, controlled studies did not confirm
these observations.41,42
Endocannabinoids
Endocannabinoids, such as anandamide or N-palmitoyl
ethanolamine, are promising new compounds that activate
cannabinoid receptors in the skin. In uncontrolled studies
they were in therapy for pruritus in atopic dermatitis, chronic
renal failure, prurigo nodularis, and in anal pruritus.43-46

Systemic therapies
Antihistaminics
Antihistaminics are the most widely used antipruritic
remedies and are the treatment of choice in the histaminedependent pruritus, such as urticaria or mastocytosis.47 The
newer drugs with low lipophilicity are recommended
because they have poor penetration into central nervous
system and less commonly produce side effects. The efficacy
of antihistaminics in other types of pruritus is questionable. If
they are needed, the first generation of antihistaminics is
usually administered because of their sedative properties,
which could be helpful in pruritic patients.2,33
Opioid receptor antagonists/agonists
The data on the pathogenesis of pruritus indicate that receptor agonists partake in the central mediation of
pruritus.9 This observation led to the use of the -receptor
antagonists naltrexone and naloxone in the treatment of
various types of recalcitrant pruritus. These agents were
successfully used in uremic pruritus, cholestatic pruritus,
prurigo nodularis, and in opioid-induced pruritus.9,48,49 The
treatment can be started with oral naltrexone monotherapy
(25-150 mg/d) or with intravenous naloxone (0.02 g/kg/
min), followed by oral naltrexone.
Activation of other opioid receptors, namely -receptors,
may also produce itching relief. Nalfurafine, a selective opioid receptor agonist, has been approved in Japan for the
treatment of uremic pruritus.50 Currently, this drug is also
being tested for other indications such as atopic dermatitis.
Ondansetron
Ondansetron is a serotonin receptor 3 (5-HT3) antagonist
that might be effective in opioid-induced pruritus.9,51 Some
data had indicated its potential advantage in cholestatic
pruritus, but controlled studies failed to confirm its efficacy.
Cholestyramine
Resins, such as cholestyramine, may be helpful in pruritus
related to cholestasis. The optimal dose is 12 grams;
however, the prolonged use of this drug may lead to
deficiency of lipid-soluble vitamins. The treatment is also

A. Reich et al.
frequently connected with nausea, flatulence, and constipation, which limit their wide usage.
Gabapentin and pregabalin
Gabapentin and pregabalin are antiepileptic agents that
decrease neuronal transmission. Both drugs were successfully used in neuropathic pruritus (postherpetic itch, brachioradial pruritus) and in severe pruritus of chronic renal failure,
cholestasis, and after burns. The initial dose of gabapentin is
300 mg/d and can be gradually (of about 300 mg every third
day) increased to the most effective dose (the maximum
is 2400 mg/d).52-55 Pregabalin is administered in the initial
dose of 50 to 75 mg and can be increased to 300 mg/d.
Antidepressants
Antipruritic effect may also be observed with antidepressant drugs, mainly serotonin reuptake inhibitors such as
paroxetine or fluvoxamine. Pruritus relief was noted in
polycythemia vera, paraneoplastic pruritus, cholestatic pruritus, and prurigo nodularis.56,57 Antidepressants are usually
recommended as a second- or third-line antipruritic therapy.
Aprepitant
Aprepitant is an oral neurokinin-1 receptor antagonist,
blocking the action of substance P and is approved for the
treatment of nausea and vomiting during cancer treatment.
A recent report indicates that aprepitant may be useful for
the treatment of chronic pruritus.58 Because the substance
is very expensive and controlled studies are missing,
aprepitant cannot be recommended for use in chronic
pruritus to date.

Other therapies
Phototherapy
UVB phototherapy is the treatment of choice in uremic
pruritus and may also be helpful in the therapy for cholestatic
pruritus and HIV-associated pruritus. UVB phototherapy
decreases the number of mast cells and free nerve endings in
the skin.59 Psoralen and ultraviolet A (PUVA) treatment may
also be useful, mainly in skin diseases with pruritus such as
psoriasis, atopic dermatitis, mycosis fungoides, or lichen
planus. PUVA was also effective in pruritus accompanying
polycythemia vera and in aquagenic pruritus.
Psychotherapy
Psychotherapy is helpful in the treatment of somatoform
pruritus. Psychotherapy was also used in patients with atopic
dermatitis (combat of stress-related itching episodes) or
neurotic excoriations.
Acupuncture
Acupuncture, both classic and electroacupuncture, may
bring some benefits for patients with pruritus. The efficacy of
acupuncture was proven in patients with uremic pruritus.60

Pruritus in the elderly

21

Fig. 1

Proposed treatment algorithm of cholestatic pruritus.

Managing pruritus in specific situations


Pruritus is frequently observed in patients with cholestasis.
The proposed algorithm of the treatment of cholestatic pruritus
is demonstrated in Figure 1. Figure 2 presents the treatment of
uremic pruritus, another common subtype of systemic itch.
Pruritus associated with hypothyroidism is due to skin
dryness. Thus, in addition to adequate thyroid hormone
replacement, the pruritus responds to emollients.61 In
hyperthyroidism, pruritus usually improves with proper
correction of thyroid function. The pruritus of iron deficiency
responds to iron supplementation.61 Low doses of aspirin
(300 mg, once or twice daily) may diminished pruritus in
polycythemia vera.2 Alternatively, paroxetine may be tried.

Fig. 2

The therapy for pruritus accompanying hematologic malignancies is shown in Figure 3. In patients with solid tumors,
the treatment of pruritus should be started with paroxetine or
mirtazapine, or both drugs together.
Pruritus in HIV-infected individuals is frequently related
to comorbidities, and the causative therapy should be
initiated first. If pruritus was assumed to be associated
specifically with HIV infection, indomethacin (25 mg/d)
may bring relief.2 Some benefit was also observed after
UVB phototherapy or thalidomide (100 mg/d). Localized
neuropathic itch may benefit from anesthetics or capsaicin;
in generalized itching due to neuronal damage, neuroleptics (eg, gabapentin, pregabalin, carbamazepine) should
be tried first.2,61

Proposed treatment algorithm of uremic pruritus. UVB, ultraviolet B.

22

A. Reich et al.

Fig. 3

Proposed treatment algorithm of pruritus accompanying hematologic malignancies.

Conclusions
Elderly people often complain of pruritus that may be
induced by a number of dermatologic, systemic, or
neurologic diseases, or can be of psychogenic origin.
Numerous comorbidities found in older patients frequently
complicate the determination of the cause of pruritus and
also make the treatment very difficult. Furthermore, physical
and mental deprivation may complicate the proper assessment of pruritus severity and negatively impair the patient's
compliance with complex antipruritic therapies. Taking into
account all these aspects of pruritus and older age, it must be
underlined that every patient with senile pruritus must be
rigorously examined and treated individually regarding both
the diagnostic procedures and antipruritic therapy.

References
1. Stnder S, Weisshaar E, Mettang T, et al. Clinical classification of itch:
a position paper of the International Forum for the Study of Itch. Acta
Derm Venereol 2007;87:291-4.
2. Twycross R, Greaves MW, Handwerker H, et al. Itch: scratching more
than the surface. QJM 2003;96:7-26.
3. Bernhard JD. Itch and pruritus: what are they, and how should itches be
classified? Dermatol Ther 2005;18:288-91.
4. Misery L, Alexandre S, Dutray S, et al. Functional itch disorder or
psychogenic pruritus: suggested diagnosis criteria from the French
psychodermatology group. Acta Derm Venereol 2007;87:341-4.
5. Misery L, Wallengren DJ, Weisshaar E, Zalewska A. Validation of
diagnosis criteria of functional itch disorder or psychogenic pruritus.
Acta Derm Venereol 2008;88:503-4.
6. Reich A, Stnder S, Szepietowski JC. Drug-induced pruritus: a review.
Acta Derm Venereol 2009;89:236-44.
7. Stnder S, Streit M, Darsow U, et al. Diagnostisches und therapeutisches Vorgehen bei chronischem Pruritus. J Dtsch Dermatol Ges
2006;4:350-70.

8. Shirin H, Schapiro JM, Arber N Pinkhas J, Sidi Y, Salomon F.


Erythromycin base-induced rash and liver function disturbances. Ann
Pharmacother 1992;26:1522-3.
9. Reich A, Szepietowski JC. Opioid-induced pruritus: an update. Clin
Exp Dermatol 2010;35:2-6.
10. Odeh M, Oliven A. Verapamil-associated liver injury. Harefuah
1998;134:36-7.
11. Kowdley KV, Keeffe EB, Fawaz KA. Prolonged cholestasis due to
trimethoprim sulfamethoxazole. Gastroenterology 1992;102:2148-50.
12. Larrey D, Amouyal G, Pessayre D, et al. Amitriptyline-induced
prolonged cholestasis. Gastroenterology 1988;94:200-3.
13. Metze D, Reimann S, Szpfalusi Z, Bohle B, Kraft D, Luger TA.
Persistent pruritus after hydroxyethyl starch infusion therapy: a result
of long-term storage in cutaneous nerves. Br J Dermatol 1997;136:
553-9.
14. Bernhard JD. Phantom itch, pseudophantom itch, and senile pruritus.
Int J Dermatol 1992;31:856-7.
15. Ward JR, Bernhard JD. Willan's itch and other causes of pruritus in the
elderly. Int J Dermatol 2005;44:267-73.
16. Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of
skin morbidity. Acta Derm Venereol 2009;89:339-50.
17. Yalin B, Tamer E, Toy GG, Ozta P, Hayran M, Alli N. The
prevalence of skin diseases in the elderly: analysis of 4099 geriatric
patients. Int J Dermatol 2006;45:672-6.
18. Norman RA. Xerosis and pruritus in the elderly: recognition and
management. Dermatol Ther 2003;16:254-9.
19. Beauregard S, Gilchrest BA. A survey of skin problems and skin care
regimens in the elderly. Arch Dermatol 1987;123:1638-43.
20. Grundmann SA, Stnder S. Evaluation of chronic pruritus in older
patients. Aging Health 2010;6:53-66.
21. Fisher GJ, Wang ZQ, Datta SC, Varani J, Kang S, Voorhees JJ.
Pathophysiology of premature skin aging induced by ultraviolet light.
N Engl J Med 1997;337:1419-28.
22. Landau M. Exogenous factors in skin aging. Curr Probl Dermatol
2007;35:1-13.
23. Uitto J. The role of elastin and collagen in cutaneous aging: intrinsic
aging versus photoexposure. J Drugs Dermatol 2008;7(2 suppl):s12-6.
24. Jenkins G. Molecular mechanisms of skin ageing. Mech Ageing Dev
2002;123:801-10.
25. Farage MA, Miller KW, Elsner P, Maibach HI. Functional and
physiological characteristics of the aging skin. Aging Clin Exp Res
2008;20:195-200.

Pruritus in the elderly


26. Waller JM, Maibach HI. Age and skin structure and function, a
quantitative approach (I): blood flow, pH, thickness, and ultrasound
echogenicity. Skin Res Technol 2005;11:221-35.
27. Waller JM, Maibach HI. Age and skin structure and function, a
quantitative approach (II): protein, glycosaminoglycan, water, and lipid
content and structure. Skin Res Technol 2006;12:145-54.
28. Thaipisuttikul Y. Pruritic skin diseases in the elderly. J Dermatol
1998;25:153-7.
29. Akimoto K, Yoshikawa N, Higaki Y, Kawashima M, Imokawa G.
Quantitative analysis of stratum corneum lipids in xerosis and asteatotic
eczema. J Dermatol 1993;20:1-6.
30. Szepietowski JC, Reich A. Evaluation of pruritus. Epocrates Online.
Available at: https://online.epocrates.com/u/2911612/Evaluation+of
+pruritus. Last updated: Feb 6, 2009.
31. Reich A, Heisig M, Szepietowski JC. Visual Analogue Scale as a validated
assessment of pruritus intensity. Acta Derm Venereol 2009;89:688.
32. Phan NQ, Stnder S. Assessment of pruritus intensity: correlation between
visual analogue scale, numeric rating scale and verbal rating scale in
patients with chronic pruritus. Acta Derm Venereol 2009;89:713.
33. Szepietowski J, Reich A. Pruritus: pathomechanism, clinics, treatment.
Poznan: Termedia Publishing House; 2010.
34. Wsik F, Szepietowski J, Szepietowski T, Weyde W. Relief of uraemic
pruritus after balneological therapy with a bath oil containing
polidocanol (Balneum Hermal Plus). An open clinical study. J Dermatol
Treat 1996;7:231-3.
35. Freitag G, Hoppner T. Results of a postmarketing drug monitoring
survey with a polidocanol-urea preparation for dry, itching skin. Current
Med Res Opin 1997;13:529-37.
36. Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic
dermatitis after treatment with topical doxepin cream. The Doxepin
Study Group. J Am Acad Dermatol 1994;31:613-6.
37. Drake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in
patients with eczematous dermatitis. Doxepin Study Group. Arch
Dermatol 1995;131:1403-8.
38. Smith PF, Corelli RL. Doxepin in the management of pruritus associated
with allergic cutaneous reactions. Ann Pharmacother 1997;31:633-5.
39. Wallengren J, Klinker M. Successful treatment of notalgia paresthetica
with topical capsaicin: vehicle-controlled, double-blind, crossover
study. J Am Acad Dermatol 1995;32:287-9.
40. Stnder S, Luger T, Metze D. Treatment of prurigo nodularis with
topical capsaicin. J Am Acad Dermatol 2001;44:471-8.
41. Pauli-Magnus C, Klumpp S, Alscher DM, Kuhlmann U, Mettang T.
Short-term efficacy of tacrolimus oinment in severe uremic pruritus.
Perit Dial Int 2000;20:802-3.
42. Duque MI, Yosipovitch G, Fleischer Jr AB, Willard J, Freedman BI.
Lack of efficacy of tacrolimus ointment 0.1% for treatment of
hemodialysis-related pruritus: a randomized, double-blind, vehiclecontrolled study. J Am Acad Dermatol 2005;52:519-21.
43. Szepietowski JC, Reich A, Szepietowski T. Emollients with endocannabinoids in the treatment of uraemic pruritus: discussion of the
therapeutic options. Ther Apher Dial 2005;9:277-9.
44. Stander S, Reinhardt HW, Luger TA. Topical cannabinoid agonists.
An effective new possibility for treating chronic pruritus. Hautarzt
2006;57:801-7.

23
45. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of
atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol 2008;22:
73-82.
46. Kupczyk P, Reich A, Szepietowski JC. Cannabinoid system in the skin
a possible target for future therapies in dermatology. Exp Dermatol
2009;18:669-79.
47. Kobza Black A. H1 antagonists in the management of the itch in
urticarias. Skin Pharmacol 1992;5:21-4.
48. Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of
naltrexone, an oral opiate receptor antagonist, in the treatment of
pruritus in internal and dermatological diseases. J Am Acad Dermatol
1999;41:533-9.
49. Bergasa NV, Talbot TL, Alling DW, et al. A controlled trial of naloxone
infusions for the pruritus of chronic cholestasis. Gastroenterology
1992;102:544-9.
50. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki
H. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride,
on severe itch in 337 haemodialysis patients: a Phase III, randomized,
double-blind, placebo-controlled study. Nephrol Dial Transplant
2010;25:1251-7.
51. Schworer H, Ramadori G. Treatment of pruritus: a new indication for
serotonin type 3 receptor antagonists. Clin Invest 1993;71:659-62.
52. Loosemore MP, Bordeaux JS, Bernhard JD. Gabapentin treatment for
notalgia paresthetica, a common isolated peripheral sensory neuropathy. J Eur Acad Dermatol Venereol 2007;21:1440-1.
53. Sheen MJ, Ho ST, Lee CH, Tsung YC, Chang FL. Preoperative
gabapentin prevents intrathecal morphine-induced pruritus after
orthopedic surgery. Anesth Analg 2008;106:1868-72.
54. Razeghi E, Eskandari D, Ganji MR, Meysamie AP, Togha M,
Khashayar P. Gabapentin and uremic pruritus in hemodialysis patients.
Ren Fail 2009;31:85-90.
55. Goutos I, Eldardiri M, Khan AA, Dziewulski P, Richardson PM.
Comparative evaluation of antipruritic protocols in acute burns. The
emerging value of gabapentin in the treatment of burns pruritus. J Burn
Care Res 2010;31:57-63.
56. Shaw RJ, Dayal S, Good J, Bruckner AL, Joshi SV. Psychiatric
medications for the treatment of pruritus. Psychosom Med 2007;69:
970-8.
57. Stnder S, Bckenholt B, Schrmeyer-Horst F, et al. Treatment of
chronic pruritus with the selective serotonin re-uptake inhibitors
paroxetine and fluvoxamine: results of an open-labelled, two-arm
proof-of-concept study. Acta Derm Venereol 2009;89:45-51.
58. Stnder S, Siepmann D, Luger TA. Targeting the neurokinin receptor 1
as a new antipruritic strategy: results of a case series with aprepitant.
Acta Derm Venereol 2009;89:717.
59. Szepietowski JC, Morita A, Tsuji T. Ultraviolet B induces mast cell
apoptosis: a hypothetical mechanism of ultraviolet B treatment for
uraemic pruritus. Med Hypotheses 2002;58:167-70.
60. Gao H, Zhang W, Wang Y. Acupuncture treatment for 34 cases of
uremic cutaneous pruritus. J Tradit Chin Med 2002;22:29-30.
61. Lonsdale-Eccles A, Carmichael AJ. Treatment of pruritus associated
with systemic disorders in the elderly: a review of the role of new
therapies. Drugs Aging 2003;20:197-208.

You might also like